References
- Abbas R, Chow C, Browder N, et al. (2000). In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol 19:178–84.
- Akiyama H, Kudo S, Shimizu T. (1985). The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittel-Forschung 35:1133–40.
- Bramer SL, Forbes WP, Mallikaarjun S. (1999). Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 37:1–11.
- Bramer SL, Tata PN, Vengurlekar SS, Brisson J. (2001). Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS. J Pharm Biomed Anal 26:637–50.
- Chapman TM, Goa K. (2003). Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 3:117–38.
- Cheymol G. (1993). Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 25:103–14.
- Holford N, Hashimoto Y, Sheiner LB. (1993). Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction. Population analysis of a randomised concentration controlled trial. Clin Pharmacokinet 25:506–15.
- Kambayashi J, Liu Y, Sun B, et al. (2003). Cilostazol as a unique antithrombotic agent. Curr Pharmaceut Design 9:2289–302.
- Kim YH, Ghim J-L, Jung JA, et al. (2015). Pharmacokinetic comparison of sustained-and immediate-release formulations of cilostazol after multiple oral doses in fed healthy male Korean volunteers. Drug Design, Dev Therapy 9:3571.
- Kimura Y, Tani T, Kanbe T, Watanabe K. (1985). Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittel-Forschung 35:1144–9.
- Kwon SU, Cho Y-J, Koo J-S, et al. (2005). Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36:782–6.
- Lee, H-I, Byeon, J-Y, Kim, Y-H, et al. (2018). Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites. Eur J Clin Pharmacol 74:1417–26.
- Liu Y, Fong M, Cone J, et al. (2000). Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 36:351–60.
- Liu Y, Shakur Y, Yoshitake M, et al. (2001). Cilostazol (Pletal®): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 19:369–86.
- Matsuda N, Naraoka M, Ohkuma H, et al. (2016). Effect of cilostazol on cerebral vasospasm and outcome in patients with aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled trial. Cerebrovasc Dis 42:97–105.
- Mohr J, Thompson J, Lazar RM, et al. (2001). A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New Engl J Med 345:1444–51.
- Morgan DJ, Bray KM. (1994). Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 26:292–307.
- Nirogi RV, Kandikere VN, Shukla M, et al. (2006). Simultaneous quantification of cilostazol and its primary metabolite 3, 4-dehydrocilostazol in human plasma by rapid liquid chromatography/tandem mass spectrometry. Anal Bioanal Chem 384:780–90.
- Robless P, Mikhailidis DP, Stansby GP. (2007). Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev. CD003748.
- Thompson PD, Zimet R, Forbes WP, Zhang P. (2002). Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90:1314–9.
- Wade JR, Kelman AW, Howie CA, Whiting B. (1993). Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharmaceut 21:209–22.
- Zhang L, Beal SL, Sheiner LB. (2003). Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodynam 30:387–404.